

## **HELIOSCOPIE OPENS AN ONCOLOGY DEPARTMENT**

*Helioscopie, a company specialising in the medico-surgical treatment of obesity, has just opened an Oncology Department to market its new range of implantable sites designed for parenteral treatment: Heliosite®, the implantable venous access port.*

### **Historical Activity**

The treatment of obesity is the historical activity of Helioscopie. The company was founded in 2000, thanks to the development of a high-performance gastric band, the Héliogast, and the placing into R & D of a non-surgical treatment for obesity, the Héliosphère intragastric air balloon.

### **Why an Oncology Department?**

Gastric bands have 3 elements: the band itself, a catheter and an implantable site making it possible to inject saline solution in order to adjust the tightening of the band. The Hélioscopie implantable site is almost entirely covered with silicone and is completely atraumatic for the patient. This point in particular attracted the attention of oncologists who wanted Helioscopie to develop a range of implantable sites specifically for the administration of parenteral treatment. First of all Hélioscopie developed 2 implantable sites that were particularly appreciated by the professionals and nursing staff. In order to meet the requirements put forward by the oncologists in the best way, Hélioscopie decided to open an Oncology Department. The aim of this department is to create a complete range of implantable sites making it possible to combine efficacy, treatment safety and atraumatism.

### **Functioning of Heliosite®**




Heliosite® is a range of implantable venous access ports for the parenteral administration of drugs, nutritional solutions or blood products. They make repeated blood sampling possible. These devices can be used whatever the approach, surgical or percutaneous. They are either pre-connected or to be connected.

The Heliosite® device is made up of a graduated silicone catheter, the free end of which is placed in a central vein and the other end of which is connected to the injection chamber. The injection chamber is in the form of a small box, surgically implanted in the subcutaneous tissues of the patient. The catheter-chamber connection is direct with the hermetic seal being provided by a fixing ring. In addition, the device is radio-opaque, making it possible to monitor its position by radiology.

**About Helioscopie**

Helioscopie is a French company based in Rhône-Alpes. It was created in 2000 and today has 50 personnel. The company, a leader in the treatment of obesity (gastric bands, dietary supplements), has progressively diversified and also manufactures implantable sites for nutrition and chemotherapy. Characteristics: strong investment in R & D, 13% of turnover (27 patents registered), and an international position, 60% of turnover coming from export. All Helioscopie products are designed and manufactured in France. Helioscopie received the Export Class 2004 trophy for Rhône-Alpes and the 2004 trophy for innovation from the Chamber of Commerce and Industry, Nord Isère.



**Heliosite® implantable venous access port**